Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Jonasson

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
The Lancet. Diabetes & Endocrinology|December 12, 2018
Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and SwedenHenrik Svanström, Peter Ueda, Mads Melbye, et al.
BMJ (Clinical Research Ed.)|November 16, 2018
Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort studyPeter Ueda, Henrik Svanström, Mads Melbye, et al.
Diabetes Care|December 12, 2022
Sodium-Glucose Cotransporter 2 Inhibitor Treatment and Risk of Atrial Fibrillation: Scandinavian Cohort StudyArvid Engström, Viktor Wintzell, Mads Melbye, et al.
Hepatology (Baltimore, Md.)|December 12, 2023
Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort studyArvid Engström, Viktor Wintzell, Mads Melbye, et al.
Heliyon|April 11, 2024
Simulated and measured piezoelectric energy harvesting of dynamic load in tiresHenrik Staaf, Simon Matsson, Sobhan Sepheri, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 16, 2023
Use of DPP4 Inhibitors and GLP-1 Receptor Agonists and Risk of Intestinal Obstruction: Scandinavian Cohort StudyPeter Ueda, Viktor Wintzell, Mads Melbye, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|June 25, 2024
Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort studyArvid Engström, Jonas Söderling, Anders Hviid, et al.
Diabetes, Obesity & Metabolism|April 17, 2026
Use of Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort StudyArvid Engström, Henrik Svanström, Anders Hviid, et al.
Diabetes Care|April 17, 2020
Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort StudyBjörn Pasternak, Viktor Wintzell, Björn Eliasson, et al.
BMJ (Clinical Research Ed.)|May 1, 2020
Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort studyBjörn Pasternak, Viktor Wintzell, Mads Melbye, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
The Lancet. Diabetes & Endocrinology|December 12, 2018
Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and SwedenHenrik Svanström, Peter Ueda, Mads Melbye, et al.
BMJ (Clinical Research Ed.)|November 16, 2018
Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort studyPeter Ueda, Henrik Svanström, Mads Melbye, et al.
Diabetes Care|December 12, 2022
Sodium-Glucose Cotransporter 2 Inhibitor Treatment and Risk of Atrial Fibrillation: Scandinavian Cohort StudyArvid Engström, Viktor Wintzell, Mads Melbye, et al.
Hepatology (Baltimore, Md.)|December 12, 2023
Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort studyArvid Engström, Viktor Wintzell, Mads Melbye, et al.
Heliyon|April 11, 2024
Simulated and measured piezoelectric energy harvesting of dynamic load in tiresHenrik Staaf, Simon Matsson, Sobhan Sepheri, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 16, 2023
Use of DPP4 Inhibitors and GLP-1 Receptor Agonists and Risk of Intestinal Obstruction: Scandinavian Cohort StudyPeter Ueda, Viktor Wintzell, Mads Melbye, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|June 25, 2024
Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort studyArvid Engström, Jonas Söderling, Anders Hviid, et al.
Diabetes, Obesity & Metabolism|April 17, 2026
Use of Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort StudyArvid Engström, Henrik Svanström, Anders Hviid, et al.
Diabetes Care|April 17, 2020
Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort StudyBjörn Pasternak, Viktor Wintzell, Björn Eliasson, et al.
BMJ (Clinical Research Ed.)|May 1, 2020
Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort studyBjörn Pasternak, Viktor Wintzell, Mads Melbye, et al.
Pageof 5